- Healthy adult: male or female
- Asymptomatic mono-infection with P. falciparum parasitemia with a parasite density of
1000 - 30,000 parasites/μL
- Age 18 years to 60 years
- Willingness to sign and ability to understand consent form
- Willingness and ability to return for scheduled follow up visits
- Mixed malaria infection by Giemsa smear
- History of allergy to or hypersensitivity to chloroquine, Azithromycin or other
macrolides (e.g. erythromycin, clarithromycin)
- Any of the following: a.) Antimalarial therapy administered in the past 4 weeks,
including quinine therapy or an artemisinin derivative; or b.) An antibacterial with
known antimalarial activity (including, erythromycin, doxycycline, clindamycin,
cotrimoxazole) within one week prior to enrollment into the study
- Fever, history of fever in past 48 hours, or signs/symptoms of malaria (including
acute or subacute headache, nausea, or vomiting)
- Inability to swallow oral medication
- Laboratory evidence or history of significant cardiovascular, liver, hematologic or
renal functional abnormality
- Any situation which could prevent the patient from returning to follow up visits
- Pregnancy or breast feeding
- Any other concurrent illness that may confound the result
- Any other condition or circumstance that in the opinion of the Investigator may pose a
threat to the study participant or study